reports
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morga...
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, . The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at . If you...
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atum...
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital...
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Un...
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock unit (“RSU”) awards to 9 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Induce...
- Jonathan Moreland
NWBI NORTHWEST BANCSHARES INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
DIN DINE BRANDS GLOBAL INC.
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
TZOO TRAVELZOO
NHF NEXPOINT CREDIT STRATEGIES FUN
DMAC DIAMEDICA THERAPEUTICS INC.
ZIP ZIPRECRUITER
NRDY INC.
LIN NERDY INC.
MXF LINDE PUBLIC LIMITED COMPANY
MDRR THE MEXICO FUND
GF INC.
CBIO MEDALIST DIVERSIFIED REIT INC.
SINT THE NEW GERMANY FUND
GMRE INC.
SEVN CRESCENT BIOPHARMA INC.
SINTX TECHNOLOGIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating ...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lea...
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFN...
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily...
Texas Capital Announces the Liquidation of the Texas Small Cap Equity ...
Texas Capital Announces the Liquidation of the Texas Small Cap Equity Index ETF DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of the Texas Capital Funds Trust (the “Board”) has authorized an orderly liquidation of the Texas Capital Texas Small Cap Equity Index ETF (NASDAQ: TXSS) (the “Fund”). After careful consideration of the Fund’s size, asset composition and growth trajectory, the Board determined that it is advisable and in the best interest of the Fund and its shareholders to liquidate the Fund. As constructed, TXSS shared some of the portfolio constituents and othe...
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Un...
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,675 shares of its common stock and granted an aggregate of 25,300 restricted stock unit (“RSU”) awards to 11 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducem...
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results...
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocr...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
RHI ROBERT HALF INTERNATIONAL INC.
EVEREST RE GROUP LTD.
FMNB FARMERS NATIONAL BANC CORP.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ASA ASA
GAM GENERAL AMERICAN INVESTORS CO. INC.
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
CHMG CHEMUNG FINANCIAL CORP.
CGEM CULLINAN ONCOLOGY INC
CLS CELESTICA INC.
GF THE NEW GERMANY FUND
ECF INC.
STBA ELLSWORTH FUND LTD
S&T BANCORP
INC.
- Jonathan Moreland
ASA ASA
NSC NORFOLK SOUTHERN CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
NWFL NORWOOD FINANCIAL CORP.
BWB BRIDGEWATER BANCSHARES
RYES PATRIOT MINEFINDERS INC.
BHRB BURKE & HERBERT BANK & TR/VA
EBC EASTERN BANKSHARES INC
VANI VIVANI MEDICAL INC
GF THE NEW GERMANY FUND
INC.
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Prefer...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2...
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Meeting (), taking place October 23-25, 2...
Texas Capital Bancshares, Inc. Announces Third Quarter 2025 Results
Texas Capital Bancshares, Inc. Announces Third Quarter 2025 Results Third quarter 2025 ROAA of 1.30% Record-level net income of $105.2 million, record-level net income available to common stockholders of $100.9 million and record-level diluted earnings per share of $2.18 for the third quarter of 2025 Record-level Book Value and record-level Tangible Book Value(2) per share of $73.05 and $73.02, respectively Growth in capital ratios continues, achieving 12.1% CET1 and 16.1% Total Capital DALLAS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent...
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Und...
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducemen...
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Results DALLAS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2025 after market on Wednesday, October 22, 2025. Executive management will host a conference call and webcast to discuss third quarter 2025 operating results on Wednesday, October 22, 2025, at 5:00 p.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number t...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Resul...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, November 6 at 4:30 p.m. ET Domestic:1 833-470-1428International:1 646-844-6383Access Code:166837 Webcast: Participants can use the dial-in numbers abov...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.